Dear Mr./Ms.,
Sanyou Biopharmaceuticals is focusing on the integrated solution of therapeutic antibody discovery and development, and could offer kinds of services for therapeutic antibody R&D.
In terms of the anti-PD-1/PD-L1 in vitro efficacy evaluation, we developed luciferase-reporter-based efficacy evaluation systems, including engineered Jurkat cell line (effector cells) expressing PD-1 & NFAT-LUC2, and engineered CHO-S cell line (artificial APC) expressing PD-L1 & anti-CD3 scFv on the membrane. This luciferase-reporter-based method has better repeatability, precision and linearity, comparing to the conventional method using primary cells as effector cells. Thus, it would be your perfect choice for the efficacy evaluation of anti-PD-1/PD-L1 therapies.
ADVANTAGES:
1) Reliable：No primary cells, more reliable than conventional method.
2) Sensitive：ng-level sensitivity.
3) Extreme Cost-performance：Only 1548 USD per sample.
Make your efficacy evaluation easier!
SERVICE:
| Service |
Input |
Time |
Output |
Price |
| Efficacy Evaluation |
Test samples & reference samples |
1~2 weeks |
Reports |
$ 1,548 per sample
|
EXAMPLE:
| Effector cells were mixed with artificial APC, followed by 18-hr incubation with serial diluted anti-PD-L1 mAb, atezolizumab. Then, the luminescence intensity was detected and the result was shown on the left. The TCR-NF-AT signal pathway could be activated by atezolizumab in a dose dependent manner. |
|
|
OTHER TARGETS:
CD40/CD40L | LAG3/MHC-II | TIGIT/PVR | IL-33/ST-2 | VEGF/VEGFR2 | Learn more.
Do you need assistance with efficacy evaluation?
Sanyou Biopharmaceuticals is a leading international High-tech biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments.
Sanyou is committed to building world-leading antibody drug discovery and development platforms of high-quality, high-throughput, integrated R&D and value transformation. Sanyou is dedicated in constructing a business ecosystem for therapeutic, R&D and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, R&D companies to open a new era for the diagnosis and treatment of human diseases.
Since the founding in the year of 2015, Sanyou has been growing rapidly. As of November 2020, Sanyou has a professional team of more than 150 employees, of which more than 70% hold a PhD or master degree, and this team is deeply experienced in R&D and industrialization of innovative drugs. Sanyou has established an integrated R&D laboratory of several thousands of square meters with advanced facilities in Caohejing Hi-Tech Park in Shanghai. The laboratory have 10 functional modules and more than 40 core technology platforms, led by a series of super-trillion phage display antibody libraries, and followed by a full range of essential R&D platforms for innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, pharmaceutical properties analysis, cell line construction, and process development. Sanyou continues to provide new technologies, new products, services and solutions of "best quality, fastest speed and lowest cost". Sanyou has established friendly business relationships with more than 100 pharmaceutical companies, drug development organizations and diagnostic product development companies around the world.
"Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients", holding these principles and beliefs, Sanyou looks forward to working with our customers and partners to build a long-term synergistic growth ecosystem and a healthy society.
You're welcome to send an email , telling us what's your need, and we will get back to you soon.
Sincerely.
Qingyang
Customer Specialist
Sanyou Biopharmaceuticals Co., Ltd.
Address: Building 6, No.188 Xinjunhuan Road,
Minhang District, Shanghai, China 201114
Email: service@sanyoubio.com
Tel: +86-21-3368 1627
Website: www.sanyoubio.com
|